MedTrace Logo

A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)

NCT02056808 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2014-08-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether increasing doses of SMT C1100 are safe, well tolerated and achieve appropriate blood levels in patients with Duchenne Muscular Dystrophy (DMD).

Conditions

Interventions

DRUG

SMT C1100

Comparison of safety and pharmacokinetic of different dosages of drug

Sponsors & Collaborators

  • Summit Therapeutics

    lead INDUSTRY

Principal Investigators

  • Stefan Spinty, MD · Alder Hey Children's NHS Foundation Trust

  • Helen Roper, MD · Heart of England NHS Foundation Trust - Heartlands Hospital

  • Imelda Hughes, MD · Central Manchester University Hospitals NHS Foundation Trust - Royal Manchester Childrens Hospital

  • Franceso Muntoni, MD · Great Ormond Street Hospital for Children NHS Foundation Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
11 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-05-31
Completion
2014-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02056808 on ClinicalTrials.gov